secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2023-10-04T23:59:59+00:00
Accession:  0001558370-23-016231
Event type: m_and_a
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CFIUS extends review of Mustang Bio facility sale to uBriGene into second 45-day phase
--------------------------------------------------------------------------------

- CFIUS initial 45-day review completed Sep 28, 2023 but not concluded; transitions to second 45-day investigation.
- CFIUS investigation to be completed no later than November 13, 2023.
- Deal involves sale of Mustang's Worcester cell processing facility and manufacturing assets to uBriGene, a Chinese CDMO subsidiary.
- CFIUS clearance was voluntarily submitted and not a condition to closing the transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023016231/0001558370-23-016231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023016231/tmb-20230928x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-016231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer